Literature DB >> 9720727

Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases.

R Pawson1, D S Richardson, A Pagliuca, S M Kelsey, S Hoque, J Breuer, A C Newland, G J Mufti.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is uncommon in the United Kingdom and has so far been restricted to people of Afro-Caribbean extraction. Between 1981 and 1995, 21 cases presented to 2 inner London teaching hospitals where 17% of the population are of Afro-Caribbean origin. Clinical presentations were similar to those of the disease in HTLV-I-endemic areas. Major responses (CR + PR) were obtained in 10/16 assessable patients (63%) treated with combination chemotherapy. However, median survival was only 5.5 months. Disease progression and opportunistic infection were the major causes of treatment failure and death. Three patients (14%) relapsed in the central nervous system (CNS). Our cases confirm the profound immunosuppression in ATLL. The poor prognosis of acute and lymphoma types of ATLL highlight the need for new approaches to treatment such as zidovudine and alpha-interferon, incorporating prophylaxis against CNS disease and opportunistic infections.

Entities:  

Mesh:

Year:  1998        PMID: 9720727     DOI: 10.3109/10428199809057597

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 2.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

3.  Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.

Authors:  Cynthia A Pise-Masison; Michael Radonovich; Kathleen Dohoney; John C Morris; Deirdre O'Mahony; Min-Jung Lee; Jane Trepel; Thomas A Waldmann; John E Janik; John N Brady
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

4.  Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Authors:  Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.